Similar to our findings in healthy individuals, both GM3- and GT1b-liposomes were taken up by CD169+ classical monocytes of all cancer patients we tested (Figures 5F, G), further supporting the potential of targeting CD169+ monocytes as a vaccination strategy. Here, SIGLEC1 is linked to cancer.